The U.S Drug Enforcement Administration (DEA) on Wednesday relaxed some restrictions on research evaluating cannabidiol, an extract of the marijuana plant, for medicinal use.

The modifications will ease some requirements imposed by the Controlled Substances Act on possession of cannabidiol (CBD) for a specific U.S. Food and Drug Administration (FDA)-approved research protocol, the DEA said.

So far, researchers who expanded the scope of their studies and required more CBD than initially approved had to request, in writing, for a modification to their DEA research registrations.

The modification had to be sanctioned by the FDA and DEA, potentially holding up research.

Read more

Related Articles